Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):VED
ONLS
АТХ:N.06.A.B Selective serotonin reuptake inhibitors
N.06.A.B.05 Paroxetine
Pharmacodynamics:Selectively blocks the reuptake of serotonin by the presynaptic membrane, which leads to an increase in serotonergic effects in the central nervous system.
Has antidepressant and anxiolytic effect with pronounced stimulating effect.
Pharmacokinetics:After oral administration, regardless of the time of ingestion, it is completely absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 5 hours.It penetrates the placental barrier and enters the breast milk.
Therapeutic effect develops after the reception. Metabolism in the liver.
The elimination half-life is 24 hours. Elimination by the kidneys (64%) and with feces (26%).
Indications:It is used in endogenous, reactive and neurotic depressive states.
V.F30-F39.F31 Bipolar affective disorder
V.F30-F39.F32 Depressive episode
V.F30-F39.F33 Recurrent depressive disorder
V.F40-F48.F41.2 Mixed anxiety and depressive disorder
Contraindications:Individual intolerance.
Carefully:Closed-angle glaucoma, hepatic insufficiency, chronic renal failure, elderly age, prostatic hyperplasia.
Pregnancy and lactation:Recommendations by FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Inside 1 time / day for 40-60 mg.
The highest daily dose: 60 mg.
The highest single dose: 60 mg.
Side effects:Central and peripheral nervous system: asthenia, drowsiness, tremor, insomnia.
The cardiovascular system: tachycardia, orthostatic hypotension.
Digestive system: dry mouth, nausea, rarely constipation.
Sense organs: disturbance of accommodation, mydriasis.
Allergic reactions.
Overdose:Increased side effects.
Treatment is symptomatic. Hemodialysis is ineffective.
Interaction:Co-administration with monoamine oxidase inhibitors leads to confusion, hyperthermia, serotonin syndrome, and death. It is recommended that the interval be applied in 14 days.
Inhibits the metabolism of astemizole, which can lead to ventricular arrhythmia.
Simultaneous use with other serotonergic drugs increases the risk of developing serotonin syndrome: fever, hyperhidrosis, central nervous system excitation, hyperreflexia, tremor, myoclonus, loss of consciousness.
Increases the concentration of tricyclic antidepressants, increasing their toxic effects.
Special instructions:During treatment is not recommended the use of alcohol, driving and work with moving mechanisms.